Neurosoft Bioelectronics and the Rise of Soft, Stretchable Brain‑Computer Interfaces

The company’s proprietary electrode platform is designed to be highly flexible and stretchable, allowing it to conform closely to the brain’s surface. According to the company, the devices are significantly more compliant than many existing neural interfaces and can cover a much larger area of the cortex.

Because the electrodes lie on the cortical surface, they can potentially:

• Access signals from large regions of the brain
• Reduce risks associated with penetrating implants
• Enable minimally invasive surgical deployment

Neurosoft is also building a neural data platform and a “foundation model” of the human cortex, trained on neural recordings collected from its devices. The goal is to improve decoding of brain signals for medical and assistive technologies.

The $7.5 million seed funding round

In May 2026, Neurosoft announced a $7.5 million oversubscribed seed financing round.

The round was led by Skybound Venture Capital, with participation from PL Capital, IAG Capital Partners, Connecticut Innovations, and other investors.

With this investment, the company says its total funding has surpassed $20 million.

The new capital will be used primarily to:

• Expand ongoing clinical trials
• Demonstrate minimally invasive implantation in human patients
• Advance regulatory pathways and commercialization in the United States
• Further develop its neural‑data platform and cortical modeling efforts

Clinical trial progress so far

Neurosoft’s technology is already being tested in early human studies. The company reports that its devices have been used in 10 patients across two ongoing clinical trials.

These studies are being conducted at:

• UTHealth Houston in the United States
• University Medical Center Utrecht (UMC Utrecht) in the Netherlands

One of the trials involves a 64‑channel soft, stretchable brain interface designed to help guide epilepsy surgery by more precisely mapping seizure‑generating brain regions.

The company has also built a GMP manufacturing line in Switzerland, holds ISO 13485 certification, and has engaged with the U.S. Food and Drug Administration through pre‑submission meetings to prepare for regulatory approval of its first commercial device.

Key products under development

Neurosoft’s platform is being developed into several clinical and assistive technologies.

SOFT ECoG™

SOFT ECoG is a family of subdural electrode arrays designed to record or stimulate brain activity during neurosurgery or for short‑term monitoring (up to about 30 days).

Potential uses include:

• Localizing epileptic tissue before surgery
• Mapping brain regions during tumor or epilepsy procedures
• Recording neural activity for research or clinical diagnostics

MINDZ™

MINDZ is a minimally invasive brain‑interface system intended to be implanted on the brain surface through a deployment mechanism.

Its first target application is localizing epileptic foci in patients with drug‑resistant epilepsy, potentially through smaller surgical openings rather than traditional craniotomies.

Synapsuit

The Synapsuit project explores decoding brain signals to control a soft wearable exosuit that assists arm and hand movement in people with severe motor disabilities.

By translating cortical signals into movement commands, the system could provide real‑time support for patients with paralysis or major motor impairment.

Where the technology stands today

Despite the promising early studies, Neurosoft’s brain‑interface devices remain investigational and are not yet approved for sale in the United States or Europe.

The company’s immediate focus is expanding clinical validation and demonstrating minimally invasive implantation methods. If those trials succeed and regulatory approval follows, the technology could offer a new category of surface‑based brain–computer interfaces designed for safer and more scalable interaction with the human brain.

In the broader neurotechnology race—alongside companies developing penetrating implants or other neural interfaces—Neurosoft is betting that soft, conformable electronics placed on the brain’s surface may provide a more practical path toward clinical adoption.